Hangzhou Highlightll Pharmaceutical Co., Ltd clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

1. Notable

   TLL-018 · Moderate to Severe Active Rheumatoid Arthritis With…TLL-018 · Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

   Enrolling by invitation only

   Hangzhou Highlightll Pharmaceutical Co., Ltd·Phase 2· NCT07748728· Registry history of NCT07748728 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.